These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 35177211)

  • 1. Development of hepatic impairment aggravates chemotherapy-induced peripheral neuropathy following oxaliplatin treatment: Evidence from clinical and preclinical studies.
    Miyamoto T; Domoto R; Sekiguchi F; Kamaguchi R; Nishimura R; Matsuno M; Tsubota M; Fujitani M; Hatanaka S; Koizumi Y; Wang D; Nishibori M; Kawabata A
    J Pharmacol Sci; 2022 Mar; 148(3):315-325. PubMed ID: 35177211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of non-macrophage cell-derived HMGB1 in oxaliplatin-induced peripheral neuropathy and its prevention by the thrombin/thrombomodulin system in rodents: negative impact of anticoagulants.
    Tsubota M; Fukuda R; Hayashi Y; Miyazaki T; Ueda S; Yamashita R; Koike N; Sekiguchi F; Wake H; Wakatsuki S; Ujiie Y; Araki T; Nishibori M; Kawabata A
    J Neuroinflammation; 2019 Oct; 16(1):199. PubMed ID: 31666085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of HMGB1 in Chemotherapy-Induced Peripheral Neuropathy.
    Sekiguchi F; Kawabata A
    Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33396481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thrombomodulin alfa prevents oxaliplatin-induced neuropathic symptoms through activation of thrombin-activatable fibrinolysis inhibitor and protein C without affecting anti-tumor activity.
    Minami T; Takeda M; Sata M; Kato H; Yano K; Sakai T; Tsujita R; Kawasaki K; Ito A
    Eur J Pharmacol; 2020 Aug; 880():173196. PubMed ID: 32416186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oxaliplatin-Induced Peripheral Neuropathy and Identification of Unique Severity Groups in Colorectal Cancer.
    Griffith KA; Zhu S; Johantgen M; Kessler MD; Renn C; Beutler AS; Kanwar R; Ambulos N; Cavaletti G; Bruna J; Briani C; Argyriou AA; Kalofonos HP; Yerges-Armstrong LM; Dorsey SG
    J Pain Symptom Manage; 2017 Nov; 54(5):701-706.e1. PubMed ID: 28743660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in chemotherapy-induced peripheral neuropathy, disturbance in activities of daily living, and depression following chemotherapy in patients with colorectal cancer: A prospective study.
    Oh PJ; Lee JR; Kim SK; Kim JH
    Eur J Oncol Nurs; 2020 Feb; 44():101676. PubMed ID: 31751847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The association between sociodemographic, clinical, and potentially preventive therapies with oxaliplatin-induced peripheral neuropathy in colorectal cancer patients.
    Hines RB; Schoborg C; Sumner T; Zhu X; Elgin EA; Zhang S
    Support Care Cancer; 2023 Jun; 31(7):386. PubMed ID: 37294347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renin-Angiotensin-Aldosterone System Inhibitors Prevent the Onset of Oxaliplatin-Induced Peripheral Neuropathy: A Retrospective Multicenter Study and in Vitro Evaluation.
    Uchida M; Ushio S; Niimura T; Takechi K; Kawazoe H; Hidaka N; Tanaka A; Araki H; Zamami Y; Ishizawa K; Kitamura Y; Sendou T; Kawasaki H; Namba H; Shibata K; Tanaka M; Takatori S
    Biol Pharm Bull; 2022 Feb; 45(2):226-234. PubMed ID: 34803077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting strategies for oxaliplatin-induced peripheral neuropathy: clinical syndrome, molecular basis, and drug development.
    Yang Y; Zhao B; Gao X; Sun J; Ye J; Li J; Cao P
    J Exp Clin Cancer Res; 2021 Oct; 40(1):331. PubMed ID: 34686205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A placebo-controlled, double-blind, randomized study of recombinant thrombomodulin (ART-123) to prevent oxaliplatin-induced peripheral neuropathy.
    Kotaka M; Saito Y; Kato T; Satake H; Makiyama A; Tsuji Y; Shinozaki K; Fujiwara T; Mizushima T; Harihara Y; Nagata N; Kurihara N; Ando M; Kusakawa G; Sakai T; Uchida Y; Takamoto M; Kimoto S; Hyodo I
    Cancer Chemother Pharmacol; 2020 Nov; 86(5):607-618. PubMed ID: 32965539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Time-dependent discrepancies between physician-assessed and patient-reported oxaliplatin-induced peripheral neuropathy in patients with metastatic colorectal cancer who received mFOLFOX6 plus bevacizumab: a post hoc analysis (WJOG4407GSS2).
    Miura Y; Ando M; Yamazaki K; Hironaka S; Boku N; Muro K; Hyodo I
    Support Care Cancer; 2021 Jul; 29(7):3715-3723. PubMed ID: 33200233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oxaliplatin-induced peripheral neuropathy: clinical features, mechanisms, prevention and treatment.
    Kang L; Tian Y; Xu S; Chen H
    J Neurol; 2021 Sep; 268(9):3269-3282. PubMed ID: 32474658
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting lysosomal cysteine protease cathepsin S reveals immunomodulatory therapeutic strategy for oxaliplatin-induced peripheral neuropathy.
    Chen SJ; Chen LH; Yeh YM; Lin CK; Lin PC; Huang HW; Shen MR; Lin BW; Lee JC; Lee CC; Lee YF; Chiang HC; Chang JY
    Theranostics; 2021; 11(10):4672-4687. PubMed ID: 33754020
    [No Abstract]   [Full Text] [Related]  

  • 14. Caspase-Dependent HMGB1 Release from Macrophages Participates in Peripheral Neuropathy Caused by Bortezomib, a Proteasome-Inhibiting Chemotherapeutic Agent, in Mice.
    Tsubota M; Miyazaki T; Ikeda Y; Hayashi Y; Aokiba Y; Tomita S; Sekiguchi F; Wang D; Nishibori M; Kawabata A
    Cells; 2021 Sep; 10(10):. PubMed ID: 34685531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new monitoring tool CLIP test for progression of oxaliplatin-induced peripheral neuropathy: A multicenter prospective study.
    Kamei K; Ohnishi T; Nakata K; Danno K; Ohkawa A; Miyake Y; Okazaki S; Fukunaga M; Toyokawa A; Hamada T; Shindoh J; Kanazawa A
    Asia Pac J Clin Oncol; 2020 Oct; 16(5):e257-e262. PubMed ID: 32893979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Involvement of high mobility group box 1 in the development and maintenance of chemotherapy-induced peripheral neuropathy in rats.
    Nishida T; Tsubota M; Kawaishi Y; Yamanishi H; Kamitani N; Sekiguchi F; Ishikura H; Liu K; Nishibori M; Kawabata A
    Toxicology; 2016 Jul; 365():48-58. PubMed ID: 27474498
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rosmarinic Acid Mitigates Mitochondrial Dysfunction and Spinal Glial Activation in Oxaliplatin-induced Peripheral Neuropathy.
    Areti A; Komirishetty P; Kalvala AK; Nellaiappan K; Kumar A
    Mol Neurobiol; 2018 Sep; 55(9):7463-7475. PubMed ID: 29427084
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The associations of oxaliplatin-induced peripheral neuropathy, sociodemographic characteristics, and clinical characteristics with time to fall in older adults with colorectal cancer.
    Hines RB; Schoborg C; Sumner T; Thiesfeldt DL; Zhang S
    Am J Epidemiol; 2024 Sep; 193(9):1271-1280. PubMed ID: 38751324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hemoglobin, Body Mass Index, and Age as Risk Factors for Paclitaxel- and Oxaliplatin-Induced Peripheral Neuropathy.
    Mizrahi D; Park SB; Li T; Timmins HC; Trinh T; Au K; Battaglini E; Wyld D; Henderson RD; Grimison P; Ke H; Geelan-Small P; Marker J; Wall B; Goldstein D
    JAMA Netw Open; 2021 Feb; 4(2):e2036695. PubMed ID: 33587134
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Study protocol: fish oil supplement in prevention of oxaliplatin-induced peripheral neuropathy in adjuvant colorectal cancer patients - a randomized controlled trial. (OxaNeuro).
    Gehr NL; Karlsson P; Timm S; Christensen S; Hvid CA; Peric J; Hansen TF; Lauritzen L; Finnerup NB; Ventzel L
    BMC Cancer; 2024 Feb; 24(1):168. PubMed ID: 38308227
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.